![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ATP5L2 |
Gene summary for ATP5L2 |
![]() |
Gene information | Species | Human | Gene symbol | ATP5L2 | Gene ID | 267020 |
Gene name | ATP synthase membrane subunit g like | |
Gene Alias | ATP5K2 | |
Cytomap | 22q13.2 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q7Z4Y8 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
267020 | ATP5L2 | C30 | Human | Oral cavity | OSCC | 3.77e-19 | 7.19e-01 | 0.3055 |
267020 | ATP5L2 | C08 | Human | Oral cavity | OSCC | 3.73e-03 | 9.27e-02 | 0.1919 |
267020 | ATP5L2 | C09 | Human | Oral cavity | OSCC | 1.43e-06 | 2.13e-01 | 0.1431 |
267020 | ATP5L2 | LP15 | Human | Oral cavity | LP | 7.60e-05 | 5.09e-01 | 0.2174 |
267020 | ATP5L2 | LP17 | Human | Oral cavity | LP | 1.34e-04 | 4.09e-01 | 0.2349 |
267020 | ATP5L2 | P1_cSCC | Human | Skin | cSCC | 1.36e-06 | 1.64e-01 | 0.0292 |
267020 | ATP5L2 | P2_cSCC | Human | Skin | cSCC | 1.29e-07 | 1.61e-01 | -0.024 |
267020 | ATP5L2 | P4_cSCC | Human | Skin | cSCC | 6.95e-03 | 1.48e-01 | -0.00290000000000005 |
267020 | ATP5L2 | P10_cSCC | Human | Skin | cSCC | 2.53e-11 | 2.26e-01 | 0.1017 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ATP5L2 | SNV | Missense_Mutation | rs773061051 | c.109N>A | p.Glu37Lys | p.E37K | Q7Z4Y8 | protein_coding | deleterious(0.04) | possibly_damaging(0.568) | TCGA-C5-A1MK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
ATP5L2 | SNV | Missense_Mutation | c.94T>C | p.Tyr32His | p.Y32H | Q7Z4Y8 | protein_coding | tolerated(0.37) | benign(0.006) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ATP5L2 | SNV | Missense_Mutation | rs145437748 | c.287N>A | p.Arg96His | p.R96H | Q7Z4Y8 | protein_coding | tolerated(0.34) | benign(0.025) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ATP5L2 | SNV | Missense_Mutation | c.226N>G | p.Asn76Asp | p.N76D | Q7Z4Y8 | protein_coding | deleterious(0.03) | probably_damaging(0.968) | TCGA-D1-A174-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ATP5L2 | SNV | Missense_Mutation | novel | c.77N>A | p.Arg26Gln | p.R26Q | Q7Z4Y8 | protein_coding | tolerated(0.37) | benign(0.033) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
ATP5L2 | SNV | Missense_Mutation | novel | c.115N>C | p.Val39Leu | p.V39L | Q7Z4Y8 | protein_coding | deleterious(0.05) | benign(0.196) | TCGA-55-8506-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ATP5L2 | SNV | Missense_Mutation | novel | c.289N>C | p.Gly97Arg | p.G97R | Q7Z4Y8 | protein_coding | deleterious(0.01) | probably_damaging(0.982) | TCGA-BA-A6DA-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ATP5L2 | SNV | Missense_Mutation | novel | c.253N>T | p.Thr85Ser | p.T85S | Q7Z4Y8 | protein_coding | deleterious(0.01) | benign(0.001) | TCGA-CG-5721-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |